← All trials
NCT07144956
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 15, 2025
- Primary completion
- Dec 14, 2029
- Completion date
- Dec 14, 2029
- First posted
- Aug 28, 2025
- Last posted
- Sep 10, 2025
- Enrollment
- 630
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Centre Hospitalier St AnneLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.